State filing guide
CLIA waiver application and requirements in Delaware.
Ask about my application — no payment todayDelaware's CLIA FAQ directs applicants to email the CMS-116 application pages.
Sources checked 2026-11-12 · next source check due 2026-12-12
Federal application procedure
These findings describe the linked sources. They do not establish that your facility qualifies for an exemption or that its application is ready. Facility type, ownership, personnel, locations and exact test systems can change the requirements.
Have your Delaware CLIA waiver application prepared for you — US$195
We check each test you plan to run, prepare your Delaware CMS-116 ready to sign, and give you signature and filing instructions. If our check shows that you do not need a certificate, or we cannot take your case, we refund the US$195 in full. Leave your email and we will send you the details and the payment link.
What the official sources say
- Delaware DPH states in its routine waived-testing FAQ that it follows CLIA guidelines with no additional requirements unique to Delaware. For this ordinary laboratory-certification route, no separate state laboratory license or related state licensing fee is indicated. Blood lead, professional authority and special facility/program duties remain separate.
- Delaware Division of Public Health, CLIA Program: email initial application to CLIA.Delaware@delaware.gov. CMS directory: 30 Sunnyside Road, Smyrna, DE 19977; fax 302-802-5001. Confirm an alternative filing method with the program before using directory contacts. Use the complete applicable CMS-116 04/2026 application with its signature. Include the signature on printed page 6, physical PDF sheet 7, with all applicable pages of the current application. Confirm signature acceptance and client authorization before a human emails the packet; retain transmission evidence. Confirm current processing times with DPH; the historical paper-processing estimate does not establish an electronic processing deadline.
- Form CMS-116 (04/2026), OMB expiration 04/30/2029, mandatory revised edition from November 9, 2026. For initial Certificate of Waiver, leave the initial CLIA number blank, select Waiver, complete sections 1-6 and 9-10, identify exact test systems and annual volumes, and obtain the laboratory director, owner or authorized representative signature. Include every applicable application page, including the signature on printed page 6 (physical PDF sheet 7). Record a monitored business email for mandatory electronic CMS communications. No payment with the application; retain any state-specific enclosures listed separately.
- For pediatric lead, the official archived 4459A text requires all screening/testing results within two weeks of final result, specified DPH reporting data/method, scheduled childhood screening and venous confirmation of capillary results at or above the CDC blood lead reference value. No separate analyzer permit was identified in that text. The September 2026 reproposal is a proposal with comments through December 1, 2026. Confirm the operative rule/version, DPH reporting enrollment and venous confirmation workflow with the program before arranging blood lead testing. Blood lead is confirmed case by case with the reviewer and quoted separately in writing after review.
Fees and timing
Federal Certificate of Waiver: $248 per two-year certificate, paid through Pay.gov after the electronic CMS fee coupon and CLIA ID. No payment with CMS-116 and no paper checks. Government fees are separate from WaivedLab preparation-service fees. Begin testing only after receiving the certificate; no processing or approval date is promised. Delaware DPH states in its routine waived-testing FAQ that it follows CLIA guidelines with no additional requirements unique to Delaware. For this ordinary laboratory-certification route, no separate state laboratory license or related state licensing fee is indicated. Blood lead, professional authority and special facility/program duties remain separate.
Check my test menuWhat still needs confirmation for your facility
- 1Confirm an initial, fixed, single-site office testing only its own patients with exact unmodified waived systems; review other facility types, outside referrals, mobile/multisite, PPM and non-waived testing separately.
- 2Before filing, review and sign the completed packet, confirm the accepted submission method and authorize submission; retain delivery evidence. Resolve any additional requirements for your facility before filing.
- 3Will this site perform on-site blood lead testing? Confirm reporting enrollment, deadlines, exact waived use, venous confirmation/referral and any personnel, analyzer or reimbursement duties case by case with the reviewer before including blood lead.
Frequently asked questions
What filing route does the cited Delaware guidance describe?
Delaware's CLIA FAQ directs applicants to email the CMS-116 application pages.
Which requirements are named in the cited Delaware materials?
Delaware DPH states in its routine waived-testing FAQ that it follows CLIA guidelines with no additional requirements unique to Delaware. For this ordinary laboratory-certification route, no separate state laboratory license or related state licensing fee is indicated. Blood lead, professional authority and special facility/program duties remain separate. Delaware Division of Public Health, CLIA Program: email initial application to CLIA.Delaware@delaware.gov. CMS directory: 30 Sunnyside Road, Smyrna, DE 19977; fax 302-802-5001. Confirm an alternative filing method with the program before using directory contacts. Use the complete applicable CMS-116 04/2026 application with its signature. Include the signature on printed page 6, physical PDF sheet 7, with all applicable pages of the current application. Confirm signature acceptance and client authorization before a human emails the packet; retain transmission evidence. Confirm current processing times with DPH; the historical paper-processing estimate does not establish an electronic processing deadline. Form CMS-116 (04/2026), OMB expiration 04/30/2029, mandatory revised edition from November 9, 2026. For initial Certificate of Waiver, leave the initial CLIA number blank, select Waiver, complete sections 1-6 and 9-10, identify exact test systems and annual volumes, and obtain the laboratory director, owner or authorized representative signature. Include every applicable application page, including the signature on printed page 6 (physical PDF sheet 7). Record a monitored business email for mandatory electronic CMS communications. No payment with the application; retain any state-specific enclosures listed separately. For pediatric lead, the official archived 4459A text requires all screening/testing results within two weeks of final result, specified DPH reporting data/method, scheduled childhood screening and venous confirmation of capillary results at or above the CDC blood lead reference value. No separate analyzer permit was identified in that text. The September 2026 reproposal is a proposal with comments through December 1, 2026. Confirm the operative rule/version, DPH reporting enrollment and venous confirmation workflow with the program before arranging blood lead testing. Blood lead is confirmed case by case with the reviewer and quoted separately in writing after review.
What do the sources establish about fees and timing in Delaware?
Federal Certificate of Waiver: $248 per two-year certificate, paid through Pay.gov after the electronic CMS fee coupon and CLIA ID. No payment with CMS-116 and no paper checks. Government fees are separate from WaivedLab preparation-service fees. Begin testing only after receiving the certificate; no processing or approval date is promised. Delaware DPH states in its routine waived-testing FAQ that it follows CLIA guidelines with no additional requirements unique to Delaware. For this ordinary laboratory-certification route, no separate state laboratory license or related state licensing fee is indicated. Blood lead, professional authority and special facility/program duties remain separate.
Does this page confirm CLIA approval or legal compliance in Delaware?
No. This is an educational prep checklist. It does not confirm approval, legal compliance, or waived status for any specific device. Verify every requirement with CMS, the FDA, and your state agency before testing.
Other jurisdictions
Each jurisdiction publishes its own terminology, forms, channel, signatures, and fees.
All 52jurisdictions →Official sources behind this guide
Need help with your Delaware CLIA route?
Tell us where your clinic operates and what you need to prepare or change. You can ask before you know your exact test system. We review the next facts needed before proposing any paid scope.
Request a scope inquiry — no payment today
Business inquiries only. Do not send patient information, test results, dates of birth, government identifiers, credential numbers, or documents.
From test research to your Delaware application
An analyte label does not confirm a device. The exact test system and the clinic’s state route need separate review before a filing scope or price can be confirmed.